NIAID interferon reagents a program of the National Institute of Allergy and Infectious Diseases.

Cover of: NIAID interferon reagents |

Published by U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health in [Bethesda, Md.] .

Written in English

Read online


  • Interferon.,
  • Antiviral agents.

Edition Notes

Book details

ContributionsNational Institutes of Health (U.S.)
The Physical Object
Paginationiii, 29 p. ;
Number of Pages29
ID Numbers
Open LibraryOL17666046M

Download NIAID interferon reagents

COVID Resources. Reliable information about the coronavirus (COVID) is available from the NIAID interferon reagents book Health Organization (current situation, international travel).Numerous and frequently-updated resource results are available from this ’s WebJunction has pulled together information and resources to assist library staff as they consider how to handle coronavirus.

The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers.

Materials are available through an online catalog. There is no charge for research materials, but domestic investigators will be. Office of the Director The Office of the Director (OD) provides scientific leadership, policy guidance, and overall NIAID interferon reagents book and administrative coordination for the Institute.

Extramural Divisions Three research NIAID interferon reagents book at NIAID direct and manage grants, contracts, and cooperative agreements that support research at external academic and research institutions (known as extramural research).

Connecting Researchers to Influenza Reagents. The CEIRS Reagents webpage is a searchable and filterable catalog of over 5, unique, influenza-specific reagents developed by CEIRS researchers. These reagents (plasmids, proteins, antibodies, and viruses) are available to the broader scientific community and can be requested through the CEIRS Reagents webpage.

The National Institute of Allergy and Infectious Diseases (NIAID) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic arters: North Bethesda, Maryland.

Author(s): National Institute of Allergy and Infectious Diseases (U.S.) Title(s): NIAID interferon reagents: a program of the National Institute of Allergy and Infectious Diseases. Country of Publication: United States Publisher: [Bethesda, Md.?]: U.S.

Dept. of Health and Human Services, Public Health Service, National Institutes of Health. The filarial service changed names a number of times over the years, but eventually became known as “the FR3” (Filariasis Research Reagent Resource Center), and the current contract is funded under the NIH NIAID Animal Models of Infectious Disease program ().For many filariasis investigators, the FR3 is synonymous with McCall and his efficient team of research technicians who Cited by: Filarial worms cause a variety of tropical diseases in humans; however, they are difficult to study because they have complex life cycles that require arthropod intermediate hosts and mammalian definitive hosts.

Research efforts in industrialized countries are further complicated by the fact that some filarial nematodes that cause disease in humans are restricted in host specificity to humans.

The NIAID Clinical Trial Implementation (R01) Grant is designed to support non-high-risk clinical trials, while the NIAID Clinical Trial Implementation (U01) Cooperative Agreement is designed to support high-risk clinical trials, as defined by NIAID below and in the associated policy statement (see NOT-AI).

The NIAID Clinical Trial. NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

The NIAID Clinical Trial Planning Grant will support planning for clinical trials that address high-priority research questions related to the mission and goals of the NIAID. Sufficient pre-clinical data to support the planning of the clinical trial should be available prior to submission of the R34 grant application.

Quick access to statistics from the NIH Data Book and annual reports produced by the NIH OER’s Division of Information Services. NIH Data Book Provides basic summary statistics on extramural grants and contract awards. ClinRegs is an online database of country-specific clinical research regulatory information designed to assist in planning and implementing international clinical research.

Countries are included based on NIAID's international clinical research priorities. If a country you are looking for is not included in ClinRegs, consider the following.

The NIAID Division of Intramural Research (DIR) conducts basic and clinical research in a wide range of disciplines related to immunology, allergy, and infectious diseases. DIR scientists study all aspects of infectious diseases such as AIDS, malaria, and influenza, including the causative agent, vectors, and pathogenesis in the human host.

About NIAID ChemDB. The ChemDB HIV, Opportunistic Infection and Tuberculosis Therapeutics Database is a tool developed by NIAID to compile and annotate preclinical data on compounds with potential therapeutic action against HIV/AIDS and related opportunistic infections.

This database is continually updated with information extracted from. National Institute of Allergy and Infectious Diseases (NIAID) Overview. During dual infection, the expression of interferon-g receptors on macrophages was reduced, The laboratory develops and standardizes pneumococcal assays and reference reagents, measures and quantitates antipneumococcal antibody responses, develops new pneumococcal.

The National Institute of Allergy and Infectious Diseases (NIAID)’s ClinRegs website is an online database of country-specific, clinical research regulatory information.

By providing well-documented and current information in a single place, ClinRegs serves as a central resource and time-saver for persons involved in planning and implementing. bioterrorist threats, in earlyNIH’s National Institute of Allergy and Infectious Diseases (NIAID) developed the NIAID Strategic Plan for Biodefense Research.

(See NIAID’s Web site, ) The purpose of the strategic plan is to guide the implementation of basic and translational biodefense research and to engageFile Size: 1MB. At long last, the first book to cover all important areas of interferon science in one volume.

Top scientists, including many pioneers in the field, highlight the role of interferons as research tools and as therapeutic agents in clinical applications. Edited by an experienced interferonologist. Limited published literature has described the presence of interferon beta-1a products in human milk at low levels; there are no data on effects of interferon beta-1a on milk production Therefore, developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse.

A human internal laboratory standard for interferon is prepared as outlined in Epstein and McManus and is ca ibrated against the International Reference Standard for leukocyte interferon (IFN-α), (G), which is available from the Viral Resources Branch, National Institutes of Allergy and Infectious Diseases (NIAID), Bethesda Cited by: UBI's vaccine is the eighth product and first peptide vaccine studied by NIAID's network, and one of several novel HIV vaccines expected to enter NIAID trials this year.

The NIAID trial will evaluate three doses of the vaccine. For each dose, 10 volunteers will be chosen at random to receive the vaccine containing alum adjuvant, a substance. National Institute of Allergy and Infectious Diseases (NIAID) SAR A tri-specific broadly neutralizing antibody against HIV: Phase 1: Recruiting: Antibody, Monoclonal: National Institute of Allergy and Infectious Diseases (NIAID) VRCLS: VRCLS; VRC-HIVMABAB: Phase 1/2: Recruiting: Antibody, Monoclonal.

National Institute of Allergy and Infectious Diseases–NIAID finances the largest portfolio of AIDS-related basic research of all the NIH 's basic research goals are to examine HIV entry mechanisms, cell types (host and virus), reservoirs, and latency; study the mechanisms of cellular immunity; assess the role of autoimmunity in AIDS pathogenesis; research the role of other.

Interferon Gamma-1b. In the US, Interferon Gamma-1b (interferon gamma-1b systemic) is a member of the drug class interferons and is used to treat Chronic Granulomatous Disease, Cutaneous T-cell Lymphoma, Idiopathic Pulmonary Fibrosis, Osteopetrosis and Rheumatoid Arthritis.

US matches: Interferon gamma-1b; Scheme. USAN. CAS registry number (Chemical Abstracts Service). provides accurate and independent information on more t prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.

Data sources include IBM Watson Micromedex (updated 10 Apr ), Cerner Multum™ (updated 6 Apr ), Wolters Kluwer™ 8/ The Online Books Page.

Online Books by. National Institute of Allergy and Infectious Diseases (U.S.) A Wikipedia article about this author is available. National Institute of Allergy and Infectious Diseases (U.S.): Food Allergy: An Overview () (PDF at ) National Institute of.

There is no cure or specific treatment for the Ebola virus disease that is currently approved for market, although various experimental treatments are being developed.

For past and current Ebola epidemics, treatment has been primarily supportive in nature. As of Augusttwo experimental treatments known as REGN-EB3 and mAb were found to be 90% effective.

Interferon beta is a Type I interferon. Interferon beta has 30% amino-acid homology with interferon alpha but only 1% homology with interferon gamma. Both interferon beta and interferon alpha are encoded on chromosome 9.

Interferon beta binds to the type 1 interferon. NIAID, a component of the National Institutes of Health, supports research on AIDS, tuberculosis and other infectious diseases as well as allergies and immunology. NIH is an agency of the U.S.

Public Health Service, U.S. Department of Health and Human Services. Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Listing a study does not mean it has been evaluated by the U.S. Federal Government. The Web site provides information on reagents for studying HIV and related opportunistic infections.

It also allows researches to order these reagents directly on line. The NIH AIDS Reagent Program evolved from a small bank of HIV research materials into a unique worldwide resource of state-of-the art reagents for HIV and other pathogens. A (Interferon alfa2b) for intramuscular, subcutaneous, intralesional, or - intravenous Injection is a purified sterile recombinant interferon product.

INTRON A recombinant for Injection has been classified as an alpha interferon and is a water-soluble protein with a molecular weight of 19, daltons produced by recombinant DNA Size: 1MB.

National Institute of Allergy and Infectious Disease Office of Science Management and Operations (HNM1A) Office of the Chief of Staff for the Immediate Office of the Director (HNM1J) Division of Allergy, Immunology and Transplantation (HNM6) Division of Microbiology and File Size: KB.

Interferon Gamma Release Assay. Interferon-γ release assays (IGRAs) are blood tests that detect the secretion of IFN-γ ex vivo by sampled lymphocytes after stimulation with 2 or 3 proteins that are fairly specific for M.

tuberculosis. From: Principles and Practice of Pediatric Infectious Diseases (Fourth Edition), Related terms: Mantoux.

published many original articles, reviews, and book chapters. David Jacobson-Kram, PhD, DABT, Associate Director for Pharmacology and Toxicology, CDER David Jacobson-Kram received his Ph.D. in embryology from the University of Connecticut in Between andDr.

Jacobson-Kram served as a staff fellow and then a senior staff fellow at. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.

Department of Health and Human Services. NIH is the primary federal. Interferon Gamma Release Assay (IGRA): Frequently Asked Questions Why use the IGRA Tuberculosis (TB) blood test.

Both the tuberculin skin test (TST) and IGRAs are aids in the diagnosis of TB infection and active TB disease. Neither test type can definitively File Size: KB. The new formulation is a liquid interferon beta- 1 a (IFN-p- 1 a) drug product (BG94 - packaged in pre-filled syringes.

It is produced from an acetate drug substance, which is manufactured from the commercial phosphate drug substance (BG94 18) used to. Store unopened reagents at °C. Do not use reagents after expiration date, or if turbidity is evident.

Before use, bring all reagents to room temperature (°C). Immediately after use, return to proper storage conditions. Lyophilized standards are stable until expiration date.

Interferon-γ Release Assays. A hallmark of the immune response to MTB infection is the release of interferon (IFN)–γ by CD4 cells. In the past decade, 2 standardized IFN-γ release assays (IGRAs) have been developed to measure IFN-γ responses to infection in blood by: Antibodies for proteins involved in negative regulation of type I interferon production pathways, according to their Panther/Gene Ontology Classification.Oxlade O, Schwartzman K, Menzies D.

Interferon -gamma release assays and TB screening in high -income countries: a cost effectiveness analysis. Int J Tuberc Lung Dis ; 16 Diel R, Nienhaus A, Lange C, Schaberg T. Cost optimization of screening for latent tuberculosis in close contacts.

Eur Respir J ; 35

90829 views Friday, November 20, 2020